AAV Bispecific HER2-CD3 Vectors for Metastasis Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments, including chemotherapeutics and immunotherapies, are not effective for all patients and can have significant adverse side effects, while metastases often arise from circulating tumor cells that are less susceptible to immunosuppressive solid tumor microenvironments.

Innovation Solution

Adeno-associated virus (AAV) vectors are used to deliver a bispecific fusion protein comprising a HER2 binding site and a CD3 binding site, expressed through recombinant AAV vectors, to target and kill circulating tumor cells, thereby reducing the risk of metastasis and cancer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional chemotherapeutics are used to treat cancer, then tumor cells can be destroyed, but significant adverse side effects occur and effectiveness is limited for all patients

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidadverse side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses AAV vectors as intermediaries to deliver immunotherapeutic genes that encode bispecific T cell engager proteins. These proteins act as mediators between T cells and tumor cells, enabling specific immune-mediated tumor cell destruction while avoiding the direct toxic effects of conventional chemotherapeutics on healthy tissues.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the direct mechanical/cellular toxicity mechanism of chemotherapeutics with a biological immune system-mediated mechanism. Instead of directly killing tumor cells through chemical damage, the therapy harnesses the patient's own T cells to specifically recognize and destroy tumor cells expressing the target antigen.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If immunotherapies are used to treat solid tumors, then tumor cells can be targeted specifically, but circulating tumor cells remain vulnerable due to being outside the immunosuppressive tumor microenvironment

Engineering Contradiction:

Improvetumor cell targeting specificityVSAvoidmetastasis prevention efficacy

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent designs the immunotherapy to serve multiple functions: it targets both solid tumor cells within the immunosuppressive microenvironment and circulating tumor cells outside it. The AAV vector system provides sustained expression of the bispecific protein, enabling continuous immune pressure against all forms of tumor cells, thereby preventing metastasis while maintaining specific targeting.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Duration of action of moving object

If AAV vectors are used to deliver immunotherapeutic genes, then long-term persistent immunologic pressure can be achieved, but vector complexity increases

Engineering Contradiction:

Improveimmunologic pressure persistenceVSAvoidvector structure complexity

Core Design Contradiction:

Duration of action of moving objectVSDevice complexity

Solution Approach 1:

The patent employs the AAV vector structure where the immunotherapeutic gene is nested within the viral capsid. The vector contains inverted terminal repeats (ITRs) that flank the transgene, allowing efficient packaging and delivery. This nested structure enables long-term gene expression while maintaining a relatively compact and manageable vector design.

Inventive Principle:

Principle #7Nested doll (Nesting)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The AAV vectors provide long-term, persistent immunologic pressure to prevent metastasis and cancer by targeting HER2-overexpressing cells, enhancing T-cell mediated killing of circulating tumor cells, and reducing the risk of cancer relapse.

Implementation Method 1

Adeno-associated viruses (AAV) have been used as gene therapy vectors to achieve long-term, consistent bloodstream levels of cancer immunotherapies

Methodology Applied

Scientific EffectViral transduction:

Implementation Method 2

Bispecific T cell engager proteins are recombinant fusion proteins that have been described in the prior art that bind to both tumor cells and T cells thereby stimulating destruction of the tumor cells

Methodology Applied

Scientific EffectAntibody-antigen binding:

Data Source

PatentUS20260022397A1Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis

Publication Date: 2026.01.22 VIRONEXIS BIOTHERAPEUTICS INC

AI summary

Provided herein are recombinant adeno-associated viral (rAAV) vectors expressing a bispecific fusion protein that binds HER2 and CD3, and methods of using the same for reducing the risk of, preventing, or treating metastasis. The disclosure provides for rAAV vectors for delivering a sequence encoding the bispecific fusion protein, and methods of using the same for reducing the risk of, preventing, or treating metastasis.